Harmonization of methods to quantify tumor mutational burden (TMB) will facilitate robust biomarker development and optimize clinical utilization and treatment decision-making. Friends aims to better understand the impact of assay variation on clinical outcomes, align standards, and define best practices for TMB assessment.
April 01, 2019
Optimizing TMB Use in Cancer Research and Care: The Friends of Cancer Research TMB Harmonization Effort
Partner Webinar
Join or Log in for Access
This content is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.